Spero Therapeutics, Inc. (SPRO) financial statements (2021 and earlier)

Company profile

Business Address 675 MASSACHUSETTS AVENUE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1278211587
Cash and cash equivalents85303487
Short-term investments425281 
Deferred costs  0 
Other undisclosed current assets121385
Total current assets:1399512492
Noncurrent Assets
Operating lease, right-of-use asset75
Property, plant and equipment2231
Deposits noncurrent assets  00
Restricted cash and investments   0
Other noncurrent assets541 
Other undisclosed noncurrent assets001 
Total noncurrent assets:141151
TOTAL ASSETS:15310612993
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6876
Accounts payable1443
Accrued liabilities1111
Employee-related liabilities4321
Debt 1  
Deferred rent credit  0
Derivative instruments and hedges, liabilities  00
Deferred revenue and credits0
Other undisclosed current liabilities81852
Total current liabilities:1427128
Noncurrent Liabilities
Long-term debt and lease obligation75  
Long-term debt, excluding current maturities00  
Operating lease, liability75
Liabilities, other than long-term debt  10
Deferred revenue and credits0
Deferred rent credit  1
Other undisclosed noncurrent liabilities(7)   
Total noncurrent liabilities:7510
Total liabilities:2132139
Stockholders' equity
Stockholders' equity attributable to parent1327511685
Preferred stock0   
Common stock0000
Additional paid in capital410274254181
Accumulated other comprehensive income (loss)(0)0(0) 
Accumulated deficit(278)(199)(139)(97)
Stockholders' equity attributable to noncontrolling interest  00
Total stockholders' equity:1327511685
TOTAL LIABILITIES AND EQUITY:15310612993

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenue, net2
Gross profit:91842
Operating expenses(88)(81)(47)(44)
Operating loss:(79)(63)(43)(42)
Nonoperating income1212
Investment income, nonoperating01  
Foreign currency transaction loss, before tax  (0)(0)
Other nonoperating income0112
Other undisclosed income from continuing operations before equity method investments, income taxes  00
Net loss:(78)(61)(42)(40)
Net income attributable to noncontrolling interest   1
Other undisclosed net income (loss) attributable to parent(0)0  
Net loss attributable to parent:(78)(61)(42)(39)
Preferred stock dividends and other adjustments(1)  (6)
Other undisclosed net income (loss) available to common stockholders, basic0  (1)
Net loss available to common stockholders, diluted:(79)(61)(42)(46)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(78)(61)(42)(40)
Other comprehensive loss  (0) 
Comprehensive loss:(78)(61)(42)(40)
Comprehensive income, net of tax, attributable to noncontrolling interest   1
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0  
Comprehensive loss, net of tax, attributable to parent:(78)(61)(42)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: